Topic Listing for Enzon Pharmaceuticals

Abelcet Accepted Lna Compound
Accounts Receivable Accounts Receivable Inventories
Accruals Medicaid Rebates Returns Chargebacks Distribution Service Fees Accrued Expenses
Accrued Expenses Other Acquired In-process Research Development
Acquisition Competing Product Acquisition Transaction
Adagen Additional Information Find
Additional Santaris Activities Additional Target Fees
Additional Targets Adjusted Financial Results
Adjusted Net Income Enzon Defines Differ Similarly Named Adverse Event
Adverse Events Advertising Promotion
Affiliate Agreement
Agreement Terms Alliance Strengthens Companies Oncology Pipelines
Amendment Amortization Acquired Intangible Assets
Amortization Acquired Intangibles Annual Meeting Stockholders 2009 Proxy Solicited Behalf Board
Annual Performance-based Incentive Compensation Annual Report Stockholders
Annual Return Percentage Anti-takeover Provisions Charter Documents Delaware Law Make Difficult
Antibody Engineering Arrangements Third-party Manufacturers Involve Significant Financial Commitments Costs
Assignment Assistance
Audit Fees Related Tax Other Authorized Disclosure
Available-for-sale Securities Background
Base Salary Basis Presentation
Because Uncertainty Pharmaceutical Pricing Reimbursement Healthcare Reform Measures Beneficial Ownership Reporting Compliance
Blocked Currency Blocking Patents Claims Infringement Stop Delay Development Proprietary
Board Directors Board Directors Voting Recommendations
Business Business Experience Executive Officers
Cash Equivalents Cash Flow Information
Cash Investments Cephalon Manufacturing Agreements
Certificate Xxxxxxxx Certification Pursuant 302 Sarbanes-oxley Act 2002
Certification Pursuant Usc §1350 Adopted 906 Sarbanes-oxley Act Changes Internal Controls
Chugai License Claim
Class Director Nominees Election 2009 Annual Meeting Code Conduct
Combination Product Commercialization
Commercialization Plan Commercialization Plans
Commitments Contingencies Common Stock
Communications Directors Compared 2006
Compared 2007 Compensation Committee Interlocks Insider Participation
Compensation Consultant Peer Group Compensation Philosophy Policies
Competing Product Compliance
Compound Acceptance Criteria Compound Selection
Compound Selection Process Comprehensive Income
Comprehensive Loss Income Concentrations Risk
Conditions Indemnification Conference Call Webcast
Confidential Information Confidential Treatment Requested
Confidentiality Agreement Conflict
Consent Independent Registered Public Accounting Firm Continue Experience Difficulties Manufacturing Materially Harm Business
Continues Improve Capital Structure--- Continuing Class Directors Serving Until 2010 Annual Meeting
Continuing Class Directors Serving Until 2011 Annual Meeting Contract Manufacturing
Contract Manufacturing Customers Terminate Agreements Fail Replace Parties Contract Manufacturing Segment
Contractual Obligations Control Target
Controlled Controls Procedures
Controls Procedures Evaluation Disclosure Coordination
Corporate Other Expense Corporate Research Development Expense
Cost Product Sales Cost Product Sales Contract Manufacturing
Cost Sales Costs Associated Exit Disposal Activities
Costs Expenses Counterparts
Countries Covering
Craig Tooman Credits Refunds
Critical Accounting Policies Estimates Current Report
Current Report Pursuant Securities Exchange Act 1934 Currently Subject Consent Solicitation Cause Substantial Disruption Business
Damages Defense Party Claims
Deferred Financing Costs Delivery
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Depend Collaborative Partners Lose They Not Apply Adequate Depend Key Personnel Not Able Retain Employees Recruit
Depend Parties Conduct Clinical Trials Product Candidates Failure Depend Patents Proprietary Rights Offer Only Limited Protection
Depocyt Derivative Financial Instruments
Derivative Instruments Develop License Alternative Technologies Unable Maintain Obtain Key
Develop Novel Cancer Therapeutics Development
Development Activities Clinical Trials Development Costs
Development Data Development Efforts
Development Plan Development Plans
Development Records Development Successful Product Candidates Highly Uncertain Due Extended
Diligent Efforts Director Independence
Directors Nomination Directors Stock Ownership Program
Disclaimer Concerning Technology Discovery Program
Disputes Disruption Supply Manufacturing Difficulties Relating Oncaspar Cause Ability
Dividends Documents Incorporated Reference
Drug Master Files Earnings Per Common Share
Effect Termination Election Director
Emea Employee Stock Purchase Plan
Employees Enforcement Enzon Pegylation Patents
Enforcement Lna Compound Patents Enforcement Lna Platform Patents
Entire Agreement Amendment Entry Material Definitive Agreement
Enzon Enzon Announces Phillip Renfro Joins Board Directors
Enzon Announces Resignation Chief Financial Officer Enzon Appoints Craig Tooman Executive Vice President Strategic
Enzon Development Plan Enzon Know-how
Enzon Pegylation Know-how Enzon Pegylation Patents
Enzon Pharmaceuticals Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals Inc 2008 Form 10-k Annual Report Enzon Pharmaceuticals Inc Name Registrant Specified Charter Person
Enzon Pharmaceuticals Inc Subsidiaries Condensed Consolidated Balance Sheets Enzon Pharmaceuticals Inc Subsidiaries Condensed Consolidated Statements Cash
Enzon Pharmaceuticals Inc Subsidiaries Condensed Consolidated Statements Operations Enzon Pharmaceuticals Inc Subsidiaries Registrant
Enzon Reports 2008 Results Enzon Reports 2nd 2009 Results
Enzon Reports Clinical Program Pegamotecan Enzon Reports Results
Enzon Reports Strong 2009 Results Enzon Right Submit Targets Target Submissions
Enzon Supply Santaris Enzon Target
Enzon Territory Enzons Board Directors Reaffirms Support Chairman Ceo
Estimates Evaluation Disclosure Controls Procedures
Even Granted Regulatory Approval Jurisdiction Not Receive Another Even Obtain Regulatory Approval Products They Not Accepted
Event Milestone Events Respect Share Capital Cause Shares Common Stock
Exact Name Registrant Specified Charter Exceptions
Exchange Information Excluding
Exclusivity Executive Deferred Compensation Plan
Exhibits Exiqon Chugai
Exiqon License Expect Incur Losses Over Next Several
Expiration Royalty Term Extension Time Achieve Development Milestones
Face Rapid Technological Change Intense Competition Harm Business Factors Affect Future Results
Failure Supply Fda
Field Financial Instruments
Financial Statements Exhibits Financial Statements Supplementary Data
Force Majeure Forecasts
Foreign Currency Transactions Foreign Exchange
Form 10-k Form 10-q
Forward Looking Statement Forward Looking Statements
Forward-looking Information Factors Affect Future Results Fresenius Biotech Development Supply Agreement
Function Joint Steering Committee Further Actions
Further Provided Gain Sale Royalty Interest
Gcp General
General Administrative General Representations Warranties
Generation Delivery Lna Compounds Glp
Gmp Governing Law Arbitration
Governmental Authority Grant Date Certificate Xxxxxxxx
Greement Hatch-waxman Certification
High Risk Early-stage Research Development Might Not Generate Highlights
Holders Immediate Release
Important Notice Regarding Availability Proxy Materials Shareholder Meeting In-vitro In-vivo Profiling Enzon
In-vivo Income Tax Benefit Provision
Income Taxes Ind
Indemnification Party Index
Indexed Returns Inex Development Commercialization Agreements
Information Press Release 2005 Undertakes Duty Update Initial Fee
Innovative Pipeline Continues Progress Insurance
Intangible Assets Interchange Targets
Interest Interpretation
Invention Inventories
Investment Equity Securities Investments Equity Securities
Investments Marketable Securities Issuance Preferred Stock Adversely Affect Rights Common Stockholders
Ivan Horak Jdpt
Jeffrey Buchalter Jsc
Know-how Labels
Launch Law Fda Policy Change Expose Competition Generic Follow-on
Laws Lcia
Leases Legal Proceedings
Licenses Licenses Enzon
Licenses Other Rights Licenses Santaris
Limitation Damages Limitations
Liquidity Capital Resources Lna Compound
Lna Compound Patent Lna Compound Patents
Lna Monomer Lna Monomers Supplied Santaris Enzon
Lna Platform Lna Platform Know-how
Lna Platform Patents Lna Technology
Locked Nucleic Acid Locked Nucleic Acid Lna Technology-based Programs
Long-lived Asset Impairment Analysis Long-lived Assets
Long-lived Assets Impairment Analysis Maa
Macugen Managements Report Internal Control Over Financial Reporting
Manufacture Lna Monomers Enzon Manufacture Selected Lna Compounds Products
Manufacturing Development Manufacturing Raw Materials
Market Information Market Unrated Debt Subject Disruptions Adverse Effect Price
Marketing Efforts Enzon Territory Marqibo Vincristine Sulfate Liposomes Injection
Medac License Agreement Meetings Attendance
Meetings Jsc Micromet Alliance
Micromet Intellectual Property Marketing Agreement Mutual Indemnification
Mutual Termination Rights Natimmune License Agreement
Need Obtain Additional Financing Meet Future Capital Needs Nektar Agreement
Nektar Alliance Nektar Cross-license License Option Agreement
Net Sales New Accounting Standards
Nominated Targets Non-us Revenue
Non-us Revenues Nonqualified Defined Contribution Other Deferred Compensation Plans
Not Applicable Not Sufficient Funds Available Pay Amounts Due 2013
Notes Payable Notes Subordinated Existing Future Indebtedness
Notice Notice Annual Meeting Stockholders Held 2009
Notices Number 0-12957
Off-balance Sheet Arrangements Oncaspar
Once Approved Products Not Accepted Marketplace Ongoing Disclosure
Ongoing Disclosure Regarding Commercialization Operations Subject Extensive Environmental Laws Regulations
Option Exercises Stock Vested 2008 Organization Basis Presentation
Other Benefits Other Events
Other Income Expense Other Information
Other Matters Other Research Development Programs
Other Rights Outlook Goals
Ovation Pharmaceuticals Inc Ovation Pharmaceuticals Inc Agreements
Overview Ownership Technology
Pacira Agreement Pagesredacted
Paragraph Notice Part
Part Other Information Part Other Information Legal Proceedings
Parties Party
Party Beneficiaries Party Rights Obtained Enzon
Party Royalties Fees Patent
Patent Term Restoration Supplemental Protection Patents Intellectual Property Rights
Patents Original Peg Technology Was Based Expired Result Paul Davit
Payment Method Payments
Payments Payment Reports Pct Application
Peg Peg Technology
Peg-intron Peg-sn38
Pegylated Pegylated Product
Pegylation Pegylation Peg Technology
Pegylation Technology Person
Phase Trial Pipeline Other Developments
Plan Attend Annual Meeting Potential Payments Termination Change Control
Pre-approval Policies Procedures Preferred Stock
Press Release Price Common Stock Been Continue Volatile Also Significantly
Price Common Stock Been Continue Volatile Significantly Affect Principles Consolidation
Product Product Candidates
Product Candidates Undergo Extensive Clinical Testing Results Highly Product Candidates Undergo Extensive Clinical Testing Results Uncertain
Product Supply Product Trademarks
Products Products Segment
Products Segment Research Development Expense Project Teams
Properties Property Equipment
Proposal Election Directors Proposal Ratification Independent Accountants
Proprietary Technologies Prosecuting Party
Prosecution Maintenance Expenses Provided
Provided Further Provided However
Proxy Statement Proxy Statement Pursuant Securities Exchange Act 1934
Publications Publicity
Purchase Price Purchase Some Compounds Utilized Products Single Source Limited
Pursuant Securities Exchange Act 1934 Quality
Quantitative Qualitative Disclosures Market Risk Ralph Del Campo
Recalls Receive Proxy Card
Recent Accounting Pronouncements Recent Highlights
Recent Operating Highlights Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Adopted 2008 Recently Issued Accounting Standards Not Adopted 2009
Reclassifications Recombinant Human Mannose-binding Lectin
Reconciliation Gaap Net Income Loss Adjusted Reconciliation Gaap Net Loss Income Adjusted
Records Records Audits
Recoveries Redacted
Regulatory Affairs Regulatory Approval
Regulatory Approval Process Highly Uncertain Not Allowed Market Regulatory Authority
Regulatory Filing Related Party Transactions
Remainder Page Intentionally Left Blank Report Compensation Committee
Report Finance Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Reports Representatives
Research Development Research Development Expenses
Reservation Period Restricted Stock Units Nonvested Shares
Restructuring Restructuring Charge
Results Operations Results Operations Financial Condition
Retirement Plans Revenue Recognition
Revenues Revoking Proxy
Rights Bankruptcy Rights Plan
Risk Factors Risks Related Business
Route 202 206 Bridgewater New Jersey 08807 Royalties
Royalties Segment Royalty Rate
Royalty Term Royalty-free Sales
Sales Marketing Sanofi-aventis License Agreements
Santaris Santaris Assistance
Santaris Know-how Santaris Pharma
Santaris Pharma Collaboration Santaris Pharma License Agreement
Santaris Supply Enzon Sarbanes-oxley Act 2002
Scas Schedule
Schedule 112 Schedule 14a
Schedule Exceptions Schedule Supply Terms Lna Monomers Supplied Santaris Enzon
Schering-plough Agreement Securities Exchange Act 1934
Securities Registered Pursuant Act Segment Information
Selected Lna Compound Selected Lna Compound Acceptance Fees
Selected Lna Compounds Selling General Administrative
Selling General Administrative Sga Selling Marketing Expenses
Seq Severability
Share Ownership Guidelines Senior Management Share-based Compensation
Share-based Compensation Plans Share-based Payment
Share-based Payments Shareholder Rights Plan
Sigma-tau Sigma-tau Pharmaceuticals Inc
Signatures Significant Agreement
Significant Agreements Significant Competition Technology Platforms Product Candidates Make Technologies
Significant Indebtedness Adversely Affect Cash Flow Ability Repay Skyepharma Agreements
Solicit Proxies Spc 2968
Spc 3042 Spin-off Research Development Operations
Sponsoring Party Standing Committees Board Directors
Stock Incentive Programs Stock Option Nonvested Share Awards
Stockholder Proposals Stockholders Equity
Stockholders8217 Equity Strategy
Strict Construction Subject Variety Types Product Liability Other Claims Based
Sublicensee Submission Matters Vote Security Holders
Subsequent Event Successful Commercialization Products Product Candidates Depend Obtaining Coverage
Summary-level Overview 2007 Compared 2006 Summary-level Overview 2008 Compared 2007
Supplemental Cash Flow Information Suppliers Experience Delays Difficulties Manufacturing Including Problems Complying
Survival Table Contents
Target Target Reservation
Target Submission Materials Technology
Term Termination Enzon
Transactions Related Persons Treatment Confidential Information
Unable Redeem 2013 Convertible Notes 2008 Fundamental Change Unable Redeem 2013 Convertible Notes Fundamental Change
United States Securities Exchange Washington 20549 Form 10-q University Copenhagen License
Valid Claim Vat
Vitro Vivo
Vote Voting Requirements
Waiver Withholding Taxes
Write-down Carrying Value Investment Write-down Goodwill
Zeneus Manufacturing Agreement 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki